Lv3
264 积分 2023-04-07 加入
还原氧化石墨烯治疗癌症的生物分子机制探讨
7天前
已完结
EphA2在结直肠癌发展、转移及耐药的研究进展
7天前
已完结
Advancements and challenges in CAR T cell therapy for pediatric brain tumors: A review
17天前
已完结
The interplay of ROS and the PI3K/Akt pathway in autophagy regulation
29天前
已完结
An overview of autophagy: Mechanism, regulation and research progress
29天前
已完结
Caught in the “Akt”: Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF
29天前
已完结
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
1个月前
已完结
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
1个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
1个月前
已完结
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
1个月前
已完结
皖公网安备34019202002308
